Tocris™ aTAG 2139

Degrader of MTH1 fusion proteins for use within the aTAG system

Supplier:  Tocris™ 6970/5

Catalog No. 69-705-TOC

Description

aTAG 2139 is a degrader of MTH1 fusion proteins for use within the aTAG system. Comprises a ligand selective for MTH1, a linker and the cereblon-binding ligand Thalidomide (Cat. No. 0652). Induces highly potent and selective degradation of fusion proteins after a 4 h incubation (DC50 = 0.27 nM; Dmax = 92.1%). Cell-permeable. Suitable for in vitro and in vivo applications.

Negative control aTAG 2139-NEG (Cat. No. 7575) also available.

Mouse DMPK properties are provided in the supplementary file (see below).

MTH1 can be expressed as a fusion with a target protein of interest using genome engineering techniques via CRISPR-mediated locus-specific knock-in. See protocol for more information.

Custom knock-in cell lines for the dTAG and aTAG platforms are available from Bio-Techne .

Specifications

• Chemical Name or Material: 6-(6-((4-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)carbamoyl)pyridin-3-yl)-N-methyl-4-(phenylamino)quinoline-3-carboxamide
• Quantity: 5 mg
• Molecular Formula: C₄₂H₃₈N₈O₈

• CAS: 2387510-81-6
• Target: TAG Degradation Platforms
• Purity: 98%

Safety and Handling

Recommended Storage : Store at -20°C